T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies targe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Hoseini, Sayed Shahabuddin, Vadlamudi, Mallika, Espinosa-Cotton, Madelyn, Tran, Hoa, Feng, Yi, Guo, Hong-fen, Xu, Hong, Cheung, Irene, Cheung, Nai-Kong V
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Clinical/Translational Cancer Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8154967/
https://ncbi.nlm.nih.gov/pubmed/34035113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002509
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars